In the latest of a series of revisions, BioHeart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, amended the terms for its IPO. The company now plans to offer 1.1 million shares at a range of $5.00-$5.50. In September, the company filed for an offering of 3.6 million shares at a range of $14-$16. Dawson James Securities is the sole underwriter on the deal.
